Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders: financial impact on a health plan.

Author information

Abstract

AIM:

To evaluate payer costs associated with treating psychiatric disorders utilizing a combinatorial pharmacogenomics test versus treatment-as-usual (TAU).

PATIENTS & METHODS:

Administrative claims data were analyzed from health plan members whose treatment was guided by GeneSight®Psychotropic testing (CPGx® cohort) and those who received TAU (TAU cohort). Reimbursed costs were calculated over the 12-month pre-index and post-index event periods.

RESULTS:

205 CPGx and 478 TAU members were included. Post-index cost savings (US$5505) drove a per-member-per-month savings of US$0.07. Disease-specific analyses resulted in similar savings.

CONCLUSION:

Use of CPGx yielded reduced spending for a commercial health plan across the patient population with psychiatric disorders, as well as among high-cost subpopulations.

KEYWORDS:

CPGx®; anxiety; bipolar disorder; combinatorial pharmacogenomics; depression; economic utility; managed care; pharmacogenomics; pharmacogenomics testing; psychiatry